Acute coronary syndrome, ACS
Conditions
Interventions
Experienced medication group:None
Pharmacogenomics group:None
Sponsors
People's Hospital of Xinjiang Uygur Autonomous Region
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.People with acute coronary syndrome and/or undergoing percutaneous coronary intervention or coronary artery bypass grafting (DAPT applicable population), hospitalized for underlying ST-segment elevation or non-ST-segment elevation ACS, at least 2 more than one of the following diagnoses are based on: (1)Ischemic symptoms persist for >20 minutes at rest; (2)ECG changes with ST segment elevation or depression of at least 1 mm in two consecutive leads; (3)Typical rise and fall of cardiac biomarker troponin I or T levels above the 99th percentile of the upper reference limit. 2.Be at least 18 years old; 3.Sign the informed consent form and be willing to cooperate with follow-up; 4.Can follow the doctor's advice to take medicine, or have a guardian.
Exclusion criteria
Exclusion criteria: 1.Patients who are or need to be treated with antiplatelet drugs other than clopidogrel and ticagrelor; 2.Patients with active pathological bleeding or a history of intracranial hemorrhage, active ulcer disease or gastrointestinal bleeding caused by other reasons; 3.Patients who plan to receive emergency coronary artery bypass grafting (CABG); 4.Patients with moderate to severe liver damage; 5.Patients who are allergic to clopidogrel or ticagrelor or aspirin finished drugs; 6.Hemophilia or thrombocytopenia; 7.Patients with a history of aspirin or other non-steroidal anti-inflammatory sensitivity, especially those with asthma, neurovascular edema or shock; 8.Patients who are or need to be treated with powerful CYP3A4 inhibitors (such as: ketoconazole, clarithromycin, nefazodone, ritonavir and atazanavir); 9.Aspirin gastrointestinal intolerance; 10.Life expectancy <1 year; 11.Have received thrombolytic therapy in the past 24 hours; 12.Patients who have known the relevant genotype in advance; 13.Pregnant or lactating women, or planning to become pregnant. 14.The subject is participating in clinical trial research of other drugs or medical devices; 15.Any known drug or alcohol dependence, difficulty in understanding the experimental protocol, and cannot but follow up in accordance with the experimental protocol; 16.The investigator considers patients who are not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite outcome of major adverse cardiovascular events and stent thrombosis; | — |
Countries
China
Contacts
Public ContactYang Yining
People's Hospital of Xinjiang Uygur Autonomous Region
Outcome results
None listed